Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

Roivant Sciences (NASDAQ:ROIV) Full Year 2025 Results

Key Financial Results

• Revenue: US$29.1m (down 77% from FY 2024).
• Net loss: US$545.0m (down by 113% from US$4.35b profit in FY 2024).
• US$0.75 loss per share (down from US$5.55 profit in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Roivant Sciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 79%. Earnings per share (EPS) exceeded analyst estimates by 27%.

Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 3.3% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Roivant Sciences you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.